1.Pulte D，Gondos A，Brenner H.Improvement in survival ofolder adults with multiple myeloma：results of an updatedperiod analysis of SEER data.Oncologist，2011，16（11）：1600-1603.

2.Kyle RA，Greipp PR.Smoldering multiple myeloma.N EnglJ Med，1980，302（24）：1347-1349.

3.陈世伦，李燕郴，张鹏，等.798例M蛋白阳性患者的临床分析.中华内科杂志，2001，40（6）：398-400.

4.武永吉，李宝鹏，张之南.125例多发性骨髓瘤临床分析.中华血液学杂志，1992，13（7）：349-351.

5.Kyle RA，Durie BG，Rajkumar SV，et al.Monoclonal gammopathyof undetermined significance（MGUS）and smoldering（asymptomatic）multiple myeloma：IMWG consensus perspectivesrisk factors for progression and guidelines for monitoringand management.Leukemia，2010，24（6）：1121-1127.

6.Kyle RA，Greipp PR.Smoldering multiple myeloma.N Engl J Med，1980，302（24）：1347-1349.

7.Kyle RA，Remstein ED，Therneau TM，et al.Clinical courseand prognosis of smoldering（asymptomatic）multiple myeloma.N Engl J Med，2007，356（25）：2582-2590.

8.Landgren O，Kyle RA，Pfeiffer RM，et al.Monoclonal gammopathy of undetermined significance（MGUS）consistently precedes multiple myeloma：a prospective study.Blood，2009，113（22）：5412-5417.

9.Rajkumar SV，Landgren O，Mateos MV.Smoldering multiple myeloma.Blood，2015，125（20）：3069-3075.

10.Morgan GJ，Walker BA，Davies FE.The genetic architecture ofmultiple myeloma.Nat Rev Cancer，2012，12（5）：335-348.

11.Chapman MA，Lawrence MS，Keats JJ，et al.Initial genomesequencing and analysis of multiple myeloma.Nature，2011，471（7339）：467-472.

12.Lopez-Corral L，Sarasquete ME，Bea S，et al.SNP-based mapping arrays reveal high genomic complexity in monoclonalgammopathies，from MGUS to myeloma status.Leukemia，2012，26（12）：2521-2529.

13.Anderson K，Lutz C，van Delft FW，et al.Genetic variegation ofclonal architecture and propagating cells in leukaemia.Nature，2011，469（7330）：356-361.

14.Kuehl WM，Bergsagel PL.Molecular pathogenesis of multiplemyeloma and its premalignant precursor.J Clin Invest，2012，122（10）：3456-3463.

15.Balakumaran A，Robey PG，Fedarko N，et al.Bone marrow microenvironment in myelomagenesis：its potentialrole in early diagnosis.Expert Rev Mol Diagn，2010，10（4）：465-480.

16.Hu J，Handisides DR，Van Valckenborgh E，et al.Targeting the multiple myeloma hypoxic niche with TH-302，a hypoxiaactivatedprodrug.Blood，2010，116（9）：1524-1527.

17.Balakumaran A，Robey PG，Fedarko N，et al.Bone marrow microenvironment in myelomagenesis：its potential role in early diagnosis.Expert Rev Mol Diagn，2010，10（4）：465-480.

18.Rajkumar SV，Kyle RA，Therneau TM，et al.Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.Blood，2005，106（3）：812-817.

19.Perez-Persona E，Vidriales MB，Mateo G，et al.New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.Blood，2007，110（7）：2586-2592.

20.Criteria for the classification of monoclonal gammopathies，multiple myeloma and related disorders：a report of theInternational Myeloma Working Group.Br J Haematol，2003，121（5）：749-757.

21.Rajkumar SV，Dimopoulos MA，Palumbo A，et al.International myeloma working group updated criteria for the diagnosis of multiple myeloma.Lancet Oncol，2014，15（12）：e538-548.

22.Hillengass J，Fechtner K，Weber MA，et al.Prognostic significanceof focal lesions in whole-body magnetic resonanceimaging in patients with asymptomatic multiple myeloma.J Clin Oncol，2010，28（9）：1606-1610.

23.Rajkumar SV，Larson D，Kyle RA.Diagnosis of smolderingmultiple myeloma.N Engl J Med，2011，365（5）：474-475.

24.Hillengass J，Landgren O.Challenges and opportunities ofnovel imaging techniques in monoclonal plasma cell disorders：imaging “early myeloma”.Leuk Lymphoma，2013，54（7）：1355-1363.

25.Zent CS，Wilson CS，Tricot G，et al.Oligoclonal protein bands and Ig isotype switching in multiple myeloma treatedwith high-dose therapy and hematopoietic cell transplantation.Blood，1998，91：3518-3523.

26.van Rhee F，Bolejack V，Hollmig K，et al.High serum freelight chain levels and their rapid reduction in response totherapy define an aggressive multiple myeloma subtype with poor prognosis.Blood，2007，110：827-832.

27.San Miguel JF，Almeida J，Mateo G，et al.Immunophenotypic evaluation of the plasma cell compartment in multiplemyeloma：a tool for comparing the efficacy of different treatment strategies and predicting outcome.Blood，2002，99：1853-1856.

28.Avet-Loiseau H，Attal M，Moreau P，et al.Genetic abnormalities and survival in multiple myeloma：the experience of the Intergroupe Francophone du Myelome.Blood，2007，109：3489-3495.

29.Decaux O，Lode L，Magrangeas F，et al.Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients：a study of the Intergroupe Francophone du Myelome.J Clin Oncol，2008，26（29）：4798-4805.

30.Kyle RA，Durie BG，Rajkumar SV，et al.Monoclonal gammopathyof undetermined significance（MGUS）and smoldering（asymptomatic）multiple myeloma：IMWG consensus perspectivesrisk factors for progression and guidelines for monitoringand management.Leukemia，2010，24（6）：1121-1127.

31.Kumar SK，Rajkumar SV，Dispenzieri A，et al.Improved survival in multiple myeloma and the impact of novel therapies.Blood.2008；111：2516-2520.

32.Cavo M，Patriarca F，Tacchetti P.Superior complete response rate and progression-free survival afterautologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma ［abstract］.Blood，2008，112：158.

33.陈世伦，邱录贵，江滨，等.硼替佐米联合沙利度胺在新诊断多发性骨髓瘤中的应用.中华内科杂志，2011，50（4）：291-294.

34.Attal M，Harousseau JL，Stoppa AM，et al.A prospective，randomized trial of autologous bone marrowtransplantation and chemotherapy in multiple myeloma.Intergroupe Francais du Myelome.N Engl JMed，1996，335：91-97.

35.Barlogie B，Kyle RA，Anderson KC，et al.Standard chemotherapy compared with high-dosechemoradiotherapy for multiple myeloma：final results of phase ⅢUS Intergroup Trial S9321.J Clin Oncol，2006，24：929-936.

36.Palumbo A，Bringhen S，Rossi D，et al.Bortezomib-melphalanprednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalanprednisonefor initial treatment of multiple myeloma：arandomized controlled trial.J Clin Oncol，2010，28（34）：5101-5109.

37.Mateos MV.How to maintain patients on long-term therapy：understanding the profile and kinetics of adverse events.LeukRes，2012，36（suppl 1）：S35-S43.

38.Terpos E，Sezer O，Croucher PI，et al.The use of bisphosphonates in multiple myeloma：recommendations of an expertpanel on behalf of the European Myeloma Network.Ann Oncol，2009，20（8）：1303-1317.

39.Berenson JR，Lichtenstein A，Porter L，et al.Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.Myeloma Aredia Study Group.N Engl J Med，1996，334（8）：488-493.

40.Modi ND，Lentzsch S.Bisphosphonates as antimyeloma drugs.Leukemia，2012，26（4）：589-594.

41.Kyle RA，Rajkumar SV.Criteria for diagnosis，staging，risk stratification and response assessment of multiple myeloma.Leukemia，2009，23：3-9.

42.Anderson K，Jagannath S，Jakubowiak A，et al.Lenalidomide，bortezomib，and dexamethasone in relapsed/refractory multiple myeloma（MM）：encouraging outcomes and tolerability in a phaseⅡstudy.J Clin Oncol，2009，27：15s，（suppl；abstract 8536）.

43.Richardson PG，Weller E，Jagannath S，et al.Multicenter，phase I，dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.J Clin Oncol.2009；27（34）：5713-5719.

44.Richardson PG，Weller E，Lonial S，et al.Lenalidomide，bortezomib，and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood.2010；116（5）：679-686.

45.Pei H，Zhang L，Luo K，et al.MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.Nature，2011，470（7332）：124-128.

46.Kroger N，Perez-Simon JA，Myint H，et al.Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.Biol Blood Marrow Transplant，2004，10：698-708.

47.Lacy M，Gertz M，Hayman S，et al.Activity of pomalidomide plus dexamethasone（Pom/dex）in dual lenalidomide/bortezomib refractory multiple myeloma（MM）［Abstract］.Presented at the American Society of Clinical Oncology（ASCO）Annual Meeting，June 4-10，2010，Chicago，Illinois，USA.

48.Richardson P，Siegel D，Baz R，et al.A phase 1/2 multi-center，randomized，open label dose escalation study to determine the maximum tolerated dose，safety，and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib.Blood，2009，114（abstract 301）.